Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
| ▸ | DRD3 | P35462 | 17/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 4/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27015441 | 0.94 | DRD3 (0.88) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL27893172 | 0.85 | DRD3 (0.73) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL7057796 | 0.83 | DRD3 (0.71) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL7053778 | 0.81 | DRD2 (0.76) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL14761629 | 0.79 | DRD3 (0.80) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL7051897 | 0.79 | DRD2 (0.69) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL16461861 | 0.78 | DRD2 (1.00) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL21802150 | 0.78 | DRD3 (1.00) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL7058045 | 0.78 | DRD2 (0.75) | DRD2DRD3HTR2AHTR1AHTR2C | |
| SCHEMBL14006089 | 0.78 | KDM4E (0.85) | DRD2DRD3HTR2AHTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | claimed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | DRD2 3/4885DRD3 10/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.